Datasets:
title: 'House Oversight: Estate Documents (Nov 12) (HOUSE_OVERSIGHT_024100)'
source: 'House Oversight: Estate Documents (Nov 12)'
sourceUrl: https://www.justice.gov/epstein
date: '2026-01-01'
category: House Oversight
eftaNumber: HOUSE_OVERSIGHT_024100
ocrPages: 1
ocrChars: 3118
ocrElapsed: 0
parseTier: external-legacy
engine: engine undisclosed (ep-nov-12.greg.technology mirror)
externalSource: greg-ep-nov-12
externalLicense: not granted
externalCredit: ep-nov-12.greg.technology
externalUrl: https://ep-nov-12.greg.technology
XIII. APPENDICES Appendix 1 Listing of Investments by Fund New Leaf Ventures II, L.P. $ amounts in millions, as of March 31, 2014 Please refer to Endnotes ,],K,L,M and N in this Appendix. Company Sector Realized or Partially Realized Investments Acadia Phamaceuticals, Inc. Ambit Biosciences, Inc. Array Biopharma Inc. Audax Health Solutions, Inc. Chimerix, Inc. Epizyme, Inc. Glumetrics, Inc. Intercept Pharmaceuticals, Inc. Kalidex Pharmaceuticals, Inc. MEI Pharma, Inc. Presidio Pharmaceuticals, Inc. Synageva BioPharma Worldheart, Inc. Therapeutics Therapeutics Therapeutics Convergence Therapeutics Therapeutics Diagnostics & Infrastructure Therapeutics Therapeutics Therapeutics Therapeutics Therapeutics Healthcare Devices Total Realized or Partially Realized Investments Advanced Cell Diagnostics, Inc. Afferent Pharmaceuticals, Inc. Altura Medical, Inc. AwarePoint Corporation Calchan Holdings LTD CardioKinetix, Inc. Convergence Pharmaceuticals, Ltd Durata Therapeutics, Inc. iRhythm Technologies, Inc. Karos Pharmaceuticals, Inc. Karus Therapeutics Ltd Karyopharm Therapeutics, Inc. Kitcheck, Inc. Neuronetics, Inc. NY Digital Health, LLC Oxford Immunotec Principia BioPharma, Inc. Spiracur, Inc TigerText, Inc. Treato Pharma Truveris, Inc. Versartis, Inc. Public Investments Diagnostics & Infrastructure Therapeutics Healthcare Devices Convergence Therapeutics Healthcare Devices Therapeutics Thera peutics Convergence Therapeutics Therapeutics Therapeutics Convergence Healthcare Devices Convergence Diagnostics & Infrastructure Therapeutics Healthcare Devices Convergence Convergence Convergence Therapeutics Therapeutics Total Unrealized Investments Total New Leaf Ventures II, L.P. Investments Vintage Year 2012 2013 2012 2011 2011 2013 2008 2012 2011 2012 2009 2009 2008 2012 2009 2010 2011 2011 2011 2010 2009 2011 2010 2012 2013 2013 2009 2012 2009 2011 2009 2012 2013 2012 2011 2011 Total Cost $ $ $ $ $ $ 7.7 10.4 9.0 3.8 20.6 3.4 10.7 10.5 2.4 9.0 11.0 10.4 17.0 125.9 9.0 11.2 10.7 12.8 5.2 12.0 7.4 25.0 11.1 7.6 5.8 1.0 3.7 20.3 0.4 11.3 9.7 12.0 4.6 3.0 6.5 21.2 20.6 232.1 358.0 89 Realized Unrealized Value Value $ $ $ 19.4 11.1 20.3 12.5 27.0 6.8 34.1 0.2 10.2 75.7 1.8 219.2 0.1 0.0 13.1 13.2 $ $
$ $ 1.6 44.9 $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ 232.4 $ 35.8 82.3 9.0 11.2 8.3 14.1 12.0 7.6 40.8 11.6 7.5 5.8 4.2 3.7 21.9 0.4 27.1 9.7 8.5 5.6 3.0 6.5 93.6 29.5 341.4 423.7 Total Value Gross Multiple Realized Portion) Gross Multiple (Total) Gross IRR $ $ $ $ $ $ $ $ $ $ 19.4 11.1 20.3 14.1 71.9 6.8 34.1 0.2 46.0 75.7 1.8 301.5 9.0 11.2 8.3 14.1 N 354.6 656.1 2.51 1.06 2.25 3.07 2.03 3.24 0.07 2.94 7.30 0.11 2.01 2.01 2.51 1.06 2.25 3.68 3.50 2.03 3.24 0.07 5.12 7.30 0.11 2.39 1.00 1.00 0.77 1.10 1.00 1.03 1.63 1.04 1.00 1.00 4.17 1.00 1.08 1.00 2.41 1.00 0.70 1.25 1.00 1.00 4.41 2.07 1.53 1.83 581.9% 13.1% 74.0% 105.6% 57.7% 1583.0% NM 323.6% -91.6% 423.2% NM 103.3% NM 40.6% -0.4% 0.0% -12.3% 5.7% NM 0.0% 1.0% 21.2% 1.6% 0.0% 0.0% 1638.7% 0.0% 2.0% 0.1% 28.3% 0.0% -8.4% 22.6% 0.0% 0.0% 129.4% 42.5% 20.4% 29.6% CONTROL NUMBER 257 - CONFIDENTIAL HOUSE_OVERSIGHT_024100